Quantum-Si reports Q1 revenue $457K, net loss $19.5M; launches Platinum instrument

Quantum-Si Inc

2024-Q1 EPS reported -$0.14 revenue$457,000

Revenue of $457,000; gross profit $269K at 59% margin.
Net loss $19.5M (vs $23.6M Q1 2023); adjusted EBITDA -$20.5M.
Full commercial launch of Platinum instrument started end of March 2024.
Version 3 sequencing kit on track for launch by end of Q3 2024.
Paula Dowdy added to Board; FY2024 financial guidance reaffirmed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Quantum-Si Inc reported first quarter ended March 31, 2024 results: revenue $457,000, net income -$19.5 million (net loss of $19.5 million). Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $457,000
Net income: -$19.5 million (net loss of $19.5 million)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

the “Company”), The Protein Sequencing Company TM , today announced financial results for the first quarter ended March 31, 2024. Press Release Highlights ● Reported revenue of $457,000 in the first quarter of 2024 ● Commenced its full commercial launch of its Platinum ® instrument at the end of March 2024 ● On track to launch version 3 of its sequencing kit,

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

Quantum-Si Inc filing history →

Source: SEC EDGAR

accession 0001140361-24-025182

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.